Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Temperature-Controlled Catheter Ablation for Paroxysmal Atrial Fibrillation: the QDOT-MICRO Workflow Sttudy

T. Potter, M. Grimaldi, HK. Jensen, J. Kautzner, P. Neuzil, J. Vijgen, A. Natale, SB. Kristiansen, P. Lukac, P. Peichl, V. Y Reddy

. 2021 ; 13 (6) : 20200460. [pub] 20210430

Language English Country United States

Document type Journal Article

Background: A novel QDOT MICRO (Biosense Webster, Inc., Irvine, CA) catheter with optimized temperature control and microelectrodes was designed to incorporate real-time temperature sensing with contact force detection and microelectrodes to streamline ablation workflow. The QDOT-MICRO feasibility study evaluated the workflow, performance, and safety of temperature-controlled catheter ablation in patients with symptomatic paroxysmal atrial fibrillation with conventional ablation setting. Methods: This was a non-randomized, single-arm, first-in-human study. The primary outcome was pulmonary vein isolation (PVI), confirmed by entrance block after adenosine and/or isoproterenol challenge. Safety outcomes included incidences of early-onset primary adverse events (AEs) and serious adverse device effects (SADEs). Device performance was evaluated via physician survey. Results: All evaluated patients (n = 42) displayed 100% PVI. Two primary AEs (4.8%) were reported: 1 pericarditis and 1 vascular pseudoaneurysm. An additional SADE of localized infection was reported in 1 patient. No stroke, patient deaths, or other unanticipated AEs were reported. Average power delivered was 32.1±4.1 W, with a mean temperature of 40.8°C±1.6°C. Mean procedure (including 20-minute wait), fluoroscopy, and radiofrequency application times were 129.8, 6.7, and 34.0 minutes, respectively. On device performance, physicians reported overall satisfactory performance with the new catheter, with highest scores for satisfaction and usefulness of the temperature indicator. Conclusions: Initial clinical experience with the novel catheter showed 100% acute PVI success and acceptable safety and device performance in temperature-controlled ablation mode. There were no deaths, stroke, or unanticipated AEs. Fluoroscopy and procedural times were short and similar or better than reported for prior generation catheters.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22001768
003      
CZ-PrNML
005      
20220112153715.0
007      
ta
008      
220107s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.4022/jafib.20200460 $2 doi
035    __
$a (PubMed)34950350
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Potter, Tom De $u OLV Hospital, Cardiology Department, Moorselbaan 164, 9300 Aalst, Belgium
245    10
$a Temperature-Controlled Catheter Ablation for Paroxysmal Atrial Fibrillation: the QDOT-MICRO Workflow Sttudy / $c T. Potter, M. Grimaldi, HK. Jensen, J. Kautzner, P. Neuzil, J. Vijgen, A. Natale, SB. Kristiansen, P. Lukac, P. Peichl, V. Y Reddy
520    9_
$a Background: A novel QDOT MICRO (Biosense Webster, Inc., Irvine, CA) catheter with optimized temperature control and microelectrodes was designed to incorporate real-time temperature sensing with contact force detection and microelectrodes to streamline ablation workflow. The QDOT-MICRO feasibility study evaluated the workflow, performance, and safety of temperature-controlled catheter ablation in patients with symptomatic paroxysmal atrial fibrillation with conventional ablation setting. Methods: This was a non-randomized, single-arm, first-in-human study. The primary outcome was pulmonary vein isolation (PVI), confirmed by entrance block after adenosine and/or isoproterenol challenge. Safety outcomes included incidences of early-onset primary adverse events (AEs) and serious adverse device effects (SADEs). Device performance was evaluated via physician survey. Results: All evaluated patients (n = 42) displayed 100% PVI. Two primary AEs (4.8%) were reported: 1 pericarditis and 1 vascular pseudoaneurysm. An additional SADE of localized infection was reported in 1 patient. No stroke, patient deaths, or other unanticipated AEs were reported. Average power delivered was 32.1±4.1 W, with a mean temperature of 40.8°C±1.6°C. Mean procedure (including 20-minute wait), fluoroscopy, and radiofrequency application times were 129.8, 6.7, and 34.0 minutes, respectively. On device performance, physicians reported overall satisfactory performance with the new catheter, with highest scores for satisfaction and usefulness of the temperature indicator. Conclusions: Initial clinical experience with the novel catheter showed 100% acute PVI success and acceptable safety and device performance in temperature-controlled ablation mode. There were no deaths, stroke, or unanticipated AEs. Fluoroscopy and procedural times were short and similar or better than reported for prior generation catheters.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Grimaldi, Massimo $u Ospedale Generale Regionale "F. Miulli" Strada Prov. 127, 70021 Acquaviva delle Fonti BA, Italy
700    1_
$a Jensen, Henrik Kjaerulf $u Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus N, Denmark
700    1_
$a Kautzner, Josef $u Institute for Clinical and Experimental Medicine, Vídeňská 1958/9, 140 21 Prague, Czech Republic
700    1_
$a Neuzil, Petr $u Na Homolce Hospital, Roentgenova 2, 150 30 Prague 5, Czech Republic
700    1_
$a Vijgen, Johan $u Jessa Ziekenhuis, Virga Jesse, Stadsomvaart 11, 3500 Hasselt, Belgium
700    1_
$a Natale, Andrea $u Texas Cardiac Arrhythmia Institute, St. David's Medical Center 3000 N. IH-35, Suite 720 Austin, TX, 78705, USA $u Interventional Electrophysiology, SCRIPPS Green Hospital, San Diego, CA, 92037, USA
700    1_
$a Kristiansen, Steen Buus $u Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus N, Denmark
700    1_
$a Lukac, Peter $u Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus N, Denmark
700    1_
$a Peichl, Petr $u Institute for Clinical and Experimental Medicine, Vídeňská 1958/9, 140 21 Prague, Czech Republic
700    1_
$a Y Reddy, Vivek $u Na Homolce Hospital, Roentgenova 2, 150 30 Prague 5, Czech Republic $u Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY, 10029, USA
773    0_
$w MED00165295 $t Journal of atrial fibrillation $x 1941-6911 $g Roč. 13, č. 6 (2021), s. 20200460
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34950350 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220107 $b ABA008
991    __
$a 20220112153711 $b ABA008
999    __
$a ind $b bmc $g 1745611 $s 1152915
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 13 $c 6 $d 20200460 $e 20210430 $i 1941-6911 $m Journal of atrial fibrillation $n J Atr Fibrillation $x MED00165295
LZP    __
$a Pubmed-20220107

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...